Figure 6. Role of Ketogenic Program in Surviving Bacterial, but Not Viral, Inflammation
(A) Plasma nonesterified fatty acids (NEFA), beta-hydroxybutyrate (BHOB), and fibroblast growth factor 21 (FGF21) after LPS, with treatment with IP PBS or
glucose. n = 10/group.
(B) Survival after 8 mg/kg IP LPS and treatment with glucose. Mice were treated with vehicle, valproic acid (VA), or levetiracetam (Keppra) starting 6hr after LPS.
p < 0.0001 for glucose+VA versus glucose and glucose+VA versus glucose+Keppra. n = 15 glucose; n = 15 glucose+VA; n = 4 glucose+Keppra.
(C) Survival after 12.5 mg/kg IP LPS in WT,Fgf21/, andPpara/mice. n = 10/group. p < 0.0001 for WT versusFgf21/; p = 0.0003 for WT versusPpara/.
(D) Plasma BHOB after 12.5 mg/kg IP LPS in WT,Fgf21/, andPpara/mice. n = 4–6/group.
(legend continued on next page)Cell 166 , 1512–1525, September 8, 2016 1521